Amgen’s R&D group has been focusing considerable attention on its development of AMG 420 — a bispecific T-cell engager, or BiTE, in brand name parlance — that it believes can point them to a competitive position with the BCMA CAR-Ts now angling for first-mover advantage, and likely better than an antibody-drug conjugate. They came to San Diego with a first look at the Phase I data that include a high rate of response for one dose that could capture some support.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
Sign in to Endpoints News
I forgot my password
Request a magic link
Access is subject to the terms in our Privacy Policy.
Request a magic link
Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours. Access is subject to the terms in our Privacy Policy.
Set a new password
We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours. Access is subject to the terms in our Privacy Policy.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.
Free Subscription
LATEST
FEATURED
SIMILAR
Subscriber Comments
There are no comments so far. Add your own?